The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery
NCT ID: NCT06507436
Last Updated: 2025-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
101 participants
INTERVENTIONAL
2024-07-31
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Study of Herombopag in Tumors-associated Thrombocytopenia
NCT05350956
Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy
NCT05442632
A Trial of Hetrombopag in Healthy and Hepatic Impairment Subjects
NCT05088642
A Real-world Study of Herombopag in the Treatment of Thrombocytopenia Related Diseases in Henan Province
NCT05130424
Herombopag + rhTPO in Severe Immune Thrombocytopenia
NCT05328804
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment group 1
Herombopag tablets
Herombopag tablets; dose 1 or dose 2, for 5 days
Herombopag placebo tablets
Herombopag placebo tablets; dose 1 or dose 2, for 5 days
Treatment group 2
Herombopag tablets
Herombopag tablets; dose 1 or dose 2, for 5 days
Herombopag placebo tablets
Herombopag placebo tablets; dose 1 or dose 2, for 5 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Herombopag tablets
Herombopag tablets; dose 1 or dose 2, for 5 days
Herombopag placebo tablets
Herombopag placebo tablets; dose 1 or dose 2, for 5 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Platelet count less than 50×10\^9/L on baseline;
3. Elective invasive procedures or surgeries that are planned.
Exclusion Criteria
2. Evidence of thrombosis (partial or complete) in the main portal vein, portal vein branches, or any part of the splenic mesenteric system at Screening;
3. Portal vein blood flow velocity rate \<10 centimeters/second at Screening;
4. There are other diseases that may cause thrombocytopenia.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jiangsu HengRui Medicine Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongshan Hospital, affiliated with Fudan University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHR8735-302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.